Cervical cancer is emerging as the “fastest-rising form of cancer” in Canada, prompting urgent calls from medical professionals for a comprehensive national strategy to combat this growing health issue. At a press conference held in Ottawa, Dr. Shannon Salvador, president of the Society of Gynecologic Oncology of Canada, highlighted the pressing need for government action, despite the federal government’s commitment in July 2025 to eliminate cervical cancer as a public health problem by 2040.
Cervical Cancer Statistics Reveal Alarming Trends
According to Dr. Salvador, an estimated 1,650 Canadians were diagnosed with cervical cancer in 2025, with approximately 430 succumbing to the disease—cases that could largely have been prevented. She described the situation as a “silent national health crisis,” stating, “While many celebrate the advancements in modern medicine, there is an alarming outlier.”
The reliance on traditional Pap tests and the stagnation of human papillomavirus (HPV) vaccination rates have become significant concerns. Currently, the HPV vaccination completion rate stands at 64 per cent, significantly below the levels required for effective elimination of the disease. Dr. Salvador expressed her dismay, stating, “This statistic is not just a medical failure, it is a policy failure.”
Calls for Modern Screening Solutions
The Society of Gynecologic Oncology of Canada is advocating for immediate changes in cervical cancer screening practices. They recommend implementing HPV DNA testing nationally and providing self-collection kits for HPV testing, which would make screening more accessible.
These self-administered tests allow individuals to collect samples from home, thereby reducing barriers including travel difficulties, historical trauma, and the lack of access to medical practitioners. Dr. Salvador emphasised the importance of these kits, particularly for women in rural, Indigenous, and underserved communities, who are often overlooked in the current healthcare framework.
Dr. Sarah Kean, the provincial lead for cervical cancer in Manitoba, echoed these sentiments, pointing out that Indigenous women face disproportionately higher diagnosis rates and worse health outcomes due to systemic barriers, including geographic isolation and poverty. “This is not due to biology,” she stated, “but rather a result of longstanding inequities within the healthcare system.”
Financial Implications of Cervical Cancer
The economic burden of cervical cancer on Canada’s healthcare system is substantial. Treatment costs were projected to reach $132 million in 2024, while screening eligible Canadians would require an additional $106 million over a five-year span.
This financial impact underscores the need for preventative measures. Dr. Salvador argued that investing in HPV vaccinations and screening could ultimately reduce both health disparities and healthcare costs.
A Global Perspective on Cervical Cancer
Cervical cancer remains a significant public health issue globally. The Canadian Cancer Society reports that it is the “fourth most diagnosed cancer and fourth leading cause of cancer death among females worldwide.” Despite previous declines in cervical cancer rates from 1984 to 2005, progress has stagnated since then, with a mere 0.3 per cent annual decrease recorded between 2005 and 2021.
As Canada strives to align with the World Health Organisation’s global strategy to eliminate cervical cancer, the emphasis must be placed on three key pillars: vaccination, HPV-based DNA screening, and access to treatment. Dr. Kean noted, “All other cancers in our country are decreasing in incidence except for the one that is entirely preventable.”
Why it Matters
The rising rates of cervical cancer in Canada signal a pressing public health crisis that requires immediate and sustained attention. With effective screening and vaccination strategies, this disease can be significantly reduced. Addressing the systemic barriers faced by vulnerable populations is not just a matter of policy—it is a moral imperative. The health of communities, particularly those historically marginalised, relies on our collective efforts to ensure equitable access to preventative care and treatment. The time for action is now.
